Drugs / ethaselen
ethaselen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02166242 | Jun 2014 → Dec 2020 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ethaselen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02166242 ↗ |
| Known as | Bbske | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035460 ↗ |
| Known as | Compound eb | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035460 ↗ |
| Known as | Ethaselen-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035460 ↗ |
| Known as | Shuang-xi-zuo-wan-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035460 ↗ |
| Action | Inhibit | “specific thioredoxin reductase inhibitor” NCT02166242 ↗ |
| Modality | Small molecule | — CHEMBL2035460 ↗ |
| Route | Oral | “patients will received oral ethaselen dispersible tablet” NCT02166242 ↗ |